AJ Lanigan: Sure. In Fact, pharma companies are producing big cash with therapies like Keytruda and Opdivo that offer with PD-1 and PD-L1. Here’s the super neat component: imagine checkpoints as targeted visitors alerts. You don’t want an immune technique that’s jogging wild similar to a freight practice in excess waiting for link from Social Bookmarking (4)